Haemonetics Corporation (HAE)

Operating return on assets (Operating ROA)

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Operating income (ttm)	US$ in thousands	221,817	201,646	188,595	172,201	186,104	170,195	167,496	178,925	156,033	139,977	132,349	110,127	80,750	40,376	45,150	79,422	89,747	136,929	137,411	128,368
Total assets	US$ in thousands	2,450,950	2,531,270	2,525,220	2,540,980	2,195,590	2,200,430	2,011,280	1,962,260	1,934,820	1,878,070	1,865,110	1,820,530	1,859,730	1,831,380	1,801,500	1,794,190	1,819,920	1,318,070	1,418,170	1,433,170
Operating ROA		9.05%	7.97%	7.47%	6.78%	8.48%	7.73%	8.33%	9.12%	8.06%	7.45%	7.10%	6.05%	4.34%	2.20%	2.51%	4.43%	4.93%	10.39%	9.69%	8.96%

March 31, 2025 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $221,817K ÷ $2,450,950K
= 9.05%

Haemonetics Corporation's operating return on assets (ROA) measures the company's ability to generate profits from its operational assets. From the data provided, we observe fluctuations in the operating ROA over time:

- The operating ROA was relatively stable in the first half of 2020, ranging from 8.96% to 10.39%.
- There was a significant decrease in operating ROA in the first quarter of 2021 to 4.93%, which may indicate a decline in operational efficiency or profitability during this period.
- The operating ROA continued to decline in the second quarter of 2021 to 4.43%, potentially signaling ongoing challenges.
- However, there was a slight improvement in operating ROA in the following quarters of 2021 and 2022.
- By the first quarter of 2023, the operating ROA increased significantly to 8.06%, suggesting a return to higher profitability.
- The operating ROA remained relatively stable and above 7% in the subsequent quarters of 2023 and 2024, indicating a sustained level of operational efficiency and profitability.
- By the first quarter of 2025, the operating ROA reached 9.05%, showing a positive trend towards higher profitability.

Overall, the analysis of Haemonetics Corporation's operating ROA demonstrates both fluctuations and improvements in the efficiency with which the company is utilizing its operational assets to generate profits over the years covered in the data.